spe-39 Antibody

What is SPE-39 and why is it important in cellular biology?

SPE-39 is a protein found exclusively in animals that plays a conserved role in lysosomal delivery. It is present in RAB5-, RAB7-, and RAB11-positive endosomes and functions through interactions with the core HOPS complex . SPE-39 serves as a previously unrecognized regulator of lysosomal biogenesis. The significance of SPE-39 lies in its involvement in fundamental cellular processes including vesicular trafficking, endosomal function, and lysosomal delivery. Understanding SPE-39 provides insights into basic cellular mechanisms that are essential for normal cell function across multiple tissues and organisms.

How are antibodies against SPE-39 typically generated and validated?

While the search results don't specifically address SPE-39 antibody generation, we can apply standard antibody development approaches. Researchers typically generate antibodies against SPE-39 by:

• Identifying antigenic regions within the SPE-39 protein sequence

• Synthesizing peptides or expressing recombinant protein fragments

• Immunizing host animals (commonly rabbits or mice)

• Screening and purifying antibodies using techniques like ELISA

Validation typically involves:

• Western blot analysis with lysates from wild-type and SPE-39 knockdown/knockout cells

• Immunocytochemistry to confirm proper subcellular localization

• Immunoprecipitation followed by mass spectrometry to verify specificity

• Comparing staining patterns with known SPE-39 interaction partners like VPS33A and VPS33B

What is the difference between monoclonal and polyclonal antibodies for SPE-39 research?

Although not explicitly described for SPE-39 in the search results, the principles of monoclonal versus polyclonal antibodies apply:

Polyclonal antibodies: Generated from multiple B-cell lineages, these recognize different epitopes on the SPE-39 protein. They provide robust detection across applications but may show batch-to-batch variability. For SPE-39 research, polyclonal antibodies would be useful for initial characterization and applications where signal amplification is needed.

Monoclonal antibodies: Derived from a single B-cell clone, these recognize a single epitope. For SPE-39 research, monoclonal antibodies (like the anti-hSPE-39 mAb mentioned in the coimmunoprecipitation experiments ) provide consistency across experiments and are particularly valuable for specific applications like tracking protein-protein interactions between SPE-39 and VPS33 homologs.

The choice depends on the research questions being addressed. Polyclonal antibodies may be preferred for applications requiring detection of denatured SPE-39, while monoclonal antibodies might be optimal for distinguishing between closely related SPE-39 homologs or for quantitative analyses.

How can I optimize immunoprecipitation protocols when studying SPE-39 interactions with the HOPS complex?

Optimizing immunoprecipitation protocols for studying SPE-39 interactions with the HOPS complex requires careful consideration of several factors:

• Lysis conditions: Since SPE-39 interacts with membrane-associated complexes, use lysis buffers containing mild detergents (0.5-1% NP-40 or Triton X-100) that maintain protein-protein interactions while solubilizing membrane proteins.

• Salt concentration: Start with physiological salt concentrations (150mM NaCl) and adjust based on the stability of the SPE-39-HOPS complex. As demonstrated in the research with human SPE-39 ortholog C14orf133, specific interactions with VPS33A and VPS33B were successfully captured under standard IP conditions .

• Antibody selection: Use validated antibodies against SPE-39 or epitope-tagged versions. The research shows successful coimmunoprecipitation using anti-hSPE-39 mAb to pull down endogenous hVPS33B from HeLa cell lysate .

• Cross-validation approaches: Perform reciprocal IPs targeting different components of the complex. For example, if you immunoprecipitate SPE-39, validate by also immunoprecipitating VPS33A or VPS33B and checking for SPE-39, as demonstrated in the research with HEK293 cells .

• Controls: Include appropriate negative controls such as normal mouse IgG or unrelated antibodies (like anti-LAMP1 mAb) that showed no precipitation of hVPS33B in control experiments .

What are the challenges in developing antibodies that distinguish between SPE-39 and its orthologs across species?

Developing species-specific antibodies for SPE-39 presents several challenges:

• Sequence conservation: While SPE-39 is conserved across animals, there are species-specific variations. Researchers need to identify regions that are unique to each ortholog (like C. elegans SPE-39 versus human C14orf133) to develop discriminating antibodies.

• Epitope selection: Careful bioinformatic analysis is necessary to identify regions that are accessible in the folded protein yet divergent across species. This may require structural prediction for SPE-39 orthologs.

• Cross-reactivity testing: Comprehensive testing against lysates from multiple species is essential. For example, antibodies raised against human SPE-39 should be tested against C. elegans lysates to ensure specificity.

• Validation in knockout/knockdown systems: Ideally, antibodies should be validated in systems where the target ortholog is absent or depleted, as shown in the SPE-39 knockdown experiments in cultured human cells .

• Application-specific optimization: An antibody that works for Western blotting might not work for immunofluorescence or immunoprecipitation due to differences in protein conformation across applications.

How do mutations in the spe-39 gene affect antibody binding and experimental design considerations?

Mutations in the spe-39 gene can significantly impact antibody binding, requiring careful experimental design:

• Epitope mapping: Determine if your antibody's epitope overlaps with common mutation sites in SPE-39. If studying C. elegans spe-39 mutants like tx12, ensure your antibody recognizes epitopes outside the mutation site .

• Protein expression levels: Some mutations may affect protein stability rather than just function. Western blotting should be performed to determine if the mutant protein is expressed at levels comparable to wild-type.

• Conformational changes: Mutations may alter protein folding, potentially masking or exposing different epitopes. Using multiple antibodies targeting different regions of SPE-39 can help address this issue.

• Cellular localization shifts: As demonstrated in C. elegans spe-39 mutants, mutations can disrupt normal cellular processes like cytokinesis and vesicular trafficking . This may change the subcellular distribution of the protein, requiring adjusted fixation and permeabilization protocols for immunocytochemistry.

• Controls and standards: Always include wild-type controls alongside mutant samples. For quantitative analyses, consider using internal standards unaffected by the spe-39 mutation.

How can antibodies against SPE-39 be used to study endosomal trafficking?

Antibodies against SPE-39 provide valuable tools for investigating endosomal trafficking pathways:

• Colocalization studies: SPE-39 antibodies can be used in immunofluorescence microscopy to examine colocalization with markers of different endosomal compartments. The research demonstrates that SPE-39 homologues are present in RAB5-, RAB7-, and RAB11-positive endosomes , allowing researchers to track changes in endosomal populations under different experimental conditions.

• Live-cell imaging: Anti-SPE-39 antibody fragments (Fab) can be fluorescently labeled and introduced into cells to monitor SPE-39 dynamics in real-time, providing insights into trafficking kinetics.

• Electron microscopy: Immunogold labeling with SPE-39 antibodies can reveal ultrastructural details of SPE-39 localization, particularly useful when studying vesicular structures like the ~100-nm vesicles that accumulate in spe-39 mutants .

• Proximity labeling: SPE-39 antibodies can be used in conjunction with techniques like BioID or APEX2 to identify proteins in close proximity to SPE-39 within endosomal compartments.

• Flow cytometry: For cells with altered endosomal trafficking, SPE-39 antibodies can be used to quantify changes in SPE-39 levels or localization across large cell populations.

What are the best immunofluorescence protocols for detecting SPE-39 in different cell types?

While specific protocols for SPE-39 immunofluorescence weren't detailed in the search results, optimal protocols would consider:

• Fixation method: For membrane-associated proteins like SPE-39, a combination of paraformaldehyde (3-4%) with a low concentration of a permeabilizing agent (0.1-0.2% Triton X-100 or 0.1% saponin) often preserves both structure and antigenicity.

• Cell type-specific considerations:

  • For HeLa cells (where SPE-39 interactions have been studied ): Standard PFA fixation followed by Triton X-100 permeabilization.

  • For C. elegans tissues: Freeze-crack methods followed by methanol/acetone fixation may better preserve structures while allowing antibody access.

  • For primary neurons or specialized cells: Gentler fixation with lower concentrations of paraformaldehyde (2%) may better preserve sensitive structures.

• Antigen retrieval: For certain tissues or highly cross-linked samples, antigen retrieval (citrate buffer pH 6.0, 95°C for 10-20 minutes) may enhance SPE-39 detection.

• Blocking and antibody dilutions: Use 5% normal serum from the species of the secondary antibody, with overnight primary antibody incubation at 4°C for optimal signal-to-noise ratio.

• Co-staining markers: Include established markers like RAB5, RAB7, RAB11, or syntaxins 7, 8, and 13, which have been shown to colocalize with SPE-39 or be affected by SPE-39 knockdown .

How do you quantitatively analyze SPE-39 distribution in cells using antibody-based methods?

Quantitative analysis of SPE-39 distribution requires rigorous methodological approaches:

• Image acquisition parameters:

  • Use consistent exposure settings across all samples

  • Capture z-stacks to account for the 3D distribution of endosomal structures

  • Acquire images at appropriate resolution to resolve individual endosomal structures (typically 100-800 nm for SPE-39-positive structures )

• Colocalization analysis:

  • Measure Pearson's or Mander's coefficients to quantify overlap between SPE-39 and markers like RAB5, RAB7, or RAB11

  • Use appropriate thresholding methods to exclude background signal

  • Report both whole-cell and region-specific colocalization metrics

• Morphometric analysis:

  • Measure size, number, and intensity of SPE-39-positive structures

  • Compare parameters between experimental conditions (e.g., control vs. VPS33B RNAi)

  • When examining effects similar to those observed in SPE-39 knockdown, quantify changes in syntaxin 7-, syntaxin 8-, and syntaxin 13-positive endosome morphology

• Subcellular fractionation complement:

  • Validate imaging results with biochemical fractionation followed by Western blotting

  • Quantify SPE-39 distribution across different membrane fractions using densitometry

• Statistical analysis:

  • Analyze adequate cell numbers (typically >30 cells per condition across 3+ independent experiments)

  • Apply appropriate statistical tests based on data distribution

  • Report effect sizes alongside p-values

How can C. elegans be used as a model system for studying SPE-39 antibody applications?

C. elegans offers several advantages as a model system for SPE-39 antibody research:

• Genetic tractability: The availability of spe-39 mutants (like tx12) provides powerful tools for antibody validation and functional studies . Researchers can use these mutants to confirm antibody specificity and investigate the consequences of SPE-39 loss.

• Cell type diversity: C. elegans allows examination of SPE-39 function across multiple tissues:

  • Spermatocytes: Study the role in formation of membranous organelles (MOs) and cytokinesis

  • Oocytes: Investigate processing of endocytosed proteins, which is disrupted in spe-39 mutants

  • Coelomocytes: Analyze general endocytic trafficking, also affected in spe-39 mutants

• Developmental staging: The ability to synchronize worm populations enables the study of SPE-39 expression and localization throughout development.

• Live imaging potential: Transparent body of C. elegans facilitates combining antibody staining with live imaging approaches.

• Evolutionary insights: As SPE-39 is conserved but shows species-specific functions, C. elegans studies provide comparative data for understanding fundamental vs. specialized roles of this protein .

What are the differences in SPE-39 expression and localization across tissues and species?

Understanding tissue-specific and species-specific variations in SPE-39 expression provides important context for antibody-based studies:

How do you design immunoprecipitation experiments to identify novel SPE-39 interacting proteins?

Designing effective immunoprecipitation experiments to discover novel SPE-39 interaction partners requires systematic approach:

• Antibody selection and validation:

  • Validate antibody specificity using SPE-39 knockdown/knockout controls

  • Confirm the antibody can immunoprecipitate known interaction partners (like VPS33A and VPS33B)

  • Consider using both N- and C-terminal targeting antibodies to capture interactions that might be masked by antibody binding

• Cell/tissue preparation:

  • Select relevant biological systems (e.g., HeLa cells, C. elegans tissues)

  • Optimize lysis conditions to preserve interactions while effectively solubilizing SPE-39

  • Consider crosslinking approaches (formaldehyde or DSP) to capture transient interactions

• IP protocol optimization:

  • Test various detergent concentrations (0.1-1% NP-40, Triton X-100, CHAPS)

  • Optimize salt concentrations (typically 100-300mM NaCl)

  • Include protease and phosphatase inhibitors to prevent degradation and preserve modification-dependent interactions

• Controls:

  • Include isotype control antibodies (like normal mouse IgG used in the human SPE-39 studies)

  • Perform parallel IPs from SPE-39-depleted cells/tissues

  • Include competing peptide controls when using peptide-raised antibodies

• Analysis methods:

  • Mass spectrometry for unbiased discovery of interaction partners

  • Western blotting for validation of specific candidate interactions

  • Consider stable isotope labeling (SILAC) approaches for quantitative comparison of interactions across conditions

How can we apply AbMAP or similar computational approaches to predict antibody binding to SPE-39?

Computational approaches like AbMAP can be applied to predict and optimize antibody binding to SPE-39:

• Epitope prediction:

  • Use sequence-based computational tools to identify likely antigenic regions within SPE-39

  • Apply structural prediction methods (if SPE-39 structure is unknown) to identify surface-exposed regions

  • Implement AbMAP-like approaches to focus on regions most likely to generate specific antibodies

• Antibody design optimization:

  • AbMAP's focus on hypervariable regions can help design antibodies with optimal binding characteristics for SPE-39

  • The contrastive augmentation approach described could help identify the most specific binding modalities for SPE-39 epitopes

  • Structure prediction capabilities can help ensure selected epitopes maintain their conformation in the native protein

• Cross-reactivity assessment:

  • Computational approaches can predict potential cross-reactivity with related proteins

  • AbMAP's ability to predict structural properties could help identify antibodies that specifically recognize SPE-39 but not related proteins

• Performance prediction:

  • Models like AbMAP can predict how antibodies might perform across different applications (Western blot, immunoprecipitation, etc.)

  • The structural prediction capabilities could help select antibodies likely to recognize native vs. denatured SPE-39

• Epitope binning simulation:

  • Computational approaches can predict which antibody combinations might be compatible for sandwich assays

  • This information is valuable for developing quantitative assays for SPE-39

What are the best approaches for troubleshooting non-specific binding when using SPE-39 antibodies?

Non-specific binding is a common challenge in antibody-based experiments. For SPE-39 antibodies, consider these troubleshooting approaches:

• Validation in knockout/knockdown systems:

  • Test antibodies in SPE-39 knockdown systems similar to those described in the research

  • Compare staining/banding patterns between wild-type and SPE-39-depleted samples

  • Any signal persisting after SPE-39 depletion indicates potential non-specific binding

• Blocking optimization:

  • Test different blocking agents (BSA, casein, normal serum, commercial blockers)

  • Increase blocking time or concentration

  • Add low concentrations (0.1-0.3%) of Triton X-100 or Tween-20 to reduce hydrophobic interactions

• Antibody dilution and incubation:

  • Perform titration series to identify optimal antibody concentration

  • Compare overnight incubation at 4°C versus shorter incubations at room temperature

  • Pre-absorb antibodies against tissues/cells lacking SPE-39 expression

• Wash stringency:

  • Increase number of washes and/or wash duration

  • Test higher salt concentrations in wash buffers (300-500mM NaCl)

  • Add low concentrations of competing proteins or detergents to washes

• Cross-validation with multiple antibodies:

  • Use antibodies targeting different regions of SPE-39

  • Compare polyclonal and monoclonal antibodies when available

  • Confirm findings with epitope-tagged versions of SPE-39, as done with hSPE-39-EGFP in the coexpression studies

How can quantitative proteomics be combined with SPE-39 antibodies for functional studies?

Integrating SPE-39 antibodies with quantitative proteomics creates powerful approaches for functional characterization:

• Immunoprecipitation-mass spectrometry (IP-MS):

  • Use SPE-39 antibodies to pull down protein complexes

  • Apply label-free quantification or isobaric labeling (TMT, iTRAQ) to compare interactomes across conditions

  • Compare interactome differences between wild-type SPE-39 and mutant versions to map functional domains

• Proximity labeling approaches:

  • Combine SPE-39 antibodies with proximity labeling techniques (BioID, APEX2)

  • Identify proteins in close proximity to SPE-39 in different subcellular compartments

  • Compare proximity profiles between normal conditions and disrupted vesicular trafficking

• Spatial proteomics:

  • Use SPE-39 antibodies for immunoaffinity purification of specific endosomal populations

  • Apply proteomics to characterize protein composition of different SPE-39-positive compartments

  • Compare proteomic profiles of RAB5-, RAB7-, and RAB11-positive endosomes containing SPE-39

• Dynamic interactome analysis:

  • Combine SPE-39 antibodies with time-course studies to capture temporal changes in interactions

  • Apply pulse-chase proteomics to track cargo movement through SPE-39-positive compartments

  • Quantify changes in interaction patterns during processes like endosome maturation

• Post-translational modification analysis:

  • Use SPE-39 antibodies to enrich the protein for PTM analysis

  • Identify regulatory modifications that affect SPE-39 interactions or localization

  • Map modification patterns to functional outcomes in vesicular trafficking

How might SPE-39 antibodies contribute to understanding lysosomal storage disorders?

Given SPE-39's role in lysosomal delivery, antibodies against this protein offer valuable tools for investigating lysosomal storage disorders:

• Diagnostic applications:

  • SPE-39 antibodies could help assess endosomal-lysosomal trafficking defects in patient samples

  • Quantitative analysis of SPE-39 distribution might serve as a biomarker for specific trafficking disorders

  • Changes in SPE-39 interactions could indicate functional defects in the pathway

• Pathophysiological mechanisms:

  • SPE-39 antibodies can help trace trafficking defects in models of lysosomal storage disorders

  • Immunofluorescence studies using SPE-39 antibodies could reveal abnormal vesicular accumulation patterns

  • Colocalization studies could identify specific steps in the endosomal-lysosomal pathway that are disrupted

• Therapeutic development:

  • SPE-39 antibodies could help screen compounds that correct trafficking defects

  • Monitoring SPE-39 localization could serve as a readout for drug efficacy

  • Antibody-based assays could help identify compounds that restore normal SPE-39 interactions

• Model system validation:

  • SPE-39 antibodies can help validate disease models by confirming relevant trafficking defects

  • Comparisons between patient samples and model systems using SPE-39 antibodies could establish model fidelity

  • Cross-species studies using SPE-39 antibodies could identify conserved disease mechanisms

• Novel disease associations:

  • Given SPE-39's role in both mannose 6-phosphate receptor-mediated cathepsin D delivery and EGFR degradation , antibodies could help investigate disorders affecting these specific pathways

What are the emerging techniques for studying the temporal dynamics of SPE-39 using antibody-based approaches?

New methodologies are expanding our ability to study the temporal aspects of SPE-39 function:

• Live-cell antibody fragment imaging:

  • Fluorescently labeled anti-SPE-39 Fab fragments can be introduced into living cells

  • This allows real-time tracking of SPE-39 movement between compartments

  • When combined with photoactivatable fluorophores, specific populations of SPE-39 can be tracked

• Fluorescence recovery after photobleaching (FRAP):

  • After immunolabeling SPE-39, specific regions can be photobleached

  • Recovery kinetics provide insights into SPE-39 mobility and exchange rates

  • This approach can reveal how SPE-39 dynamics change in disease models

• Correlative light and electron microscopy (CLEM):

  • SPE-39 antibodies can be used for fluorescence imaging followed by electron microscopy

  • This reveals ultrastructural details of SPE-39-positive compartments at specific time points

  • Particularly valuable for studying the vesicular structures affected in spe-39 mutants

• Lattice light-sheet microscopy:

  • Allows long-term 3D imaging of SPE-39-labeled structures with minimal phototoxicity

  • Can capture rapid events in vesicular trafficking not visible with conventional microscopy

  • Enables tracking of SPE-39-positive vesicles during processes like cytokinesis, which is affected in spe-39 mutants

• Optogenetic approaches:

  • Combining SPE-39 antibodies with optogenetic tools allows temporal control of trafficking

  • Light-induced clustering or dissociation of SPE-39 can reveal immediate functional consequences

  • Antibodies can then track resulting changes in endosomal organization

How can we develop antibodies that specifically recognize SPE-39 protein-protein interaction interfaces?

Developing antibodies that target specific protein-protein interaction interfaces of SPE-39 presents both challenges and opportunities:

• Epitope-specific antibody design:

  • Identify the specific regions of SPE-39 that interact with partners like VPS33A and VPS33B

  • Design peptide antigens that specifically correspond to these interaction interfaces

  • Employ structural information (when available) to design conformational epitopes

• Phage display selection strategies:

  • Use competitive elution during phage display to select antibodies that compete with natural binding partners

  • Screen for antibodies that bind SPE-39 only when not complexed with interaction partners

  • Select antibodies that recognize conformational changes induced by protein-protein interactions

• Validation approaches:

  • Test whether selected antibodies inhibit or detect known interactions (e.g., SPE-39 with VPS33A/B)

  • Perform structural studies to confirm binding to the intended interface

  • Use mutagenesis to verify epitope specificity

• Application considerations:

  • Interface-specific antibodies may be valuable for disrupting specific SPE-39 functions

  • They can serve as sensors for complex formation in live cells

  • Such antibodies could distinguish between "free" and "complexed" pools of SPE-39

• Therapeutic potential:

  • Antibodies targeting specific interaction interfaces could selectively modulate SPE-39 functions

  • This approach might allow targeting of disease-relevant interactions while preserving others

  • Humanized versions of such antibodies could have potential as therapeutics for trafficking disorders

How can CRISPR-Cas9 genome editing be integrated with SPE-39 antibody studies?

CRISPR-Cas9 technology offers powerful approaches to enhance SPE-39 antibody research:

• Endogenous tagging for antibody validation:

  • Insert epitope tags into the endogenous SPE-39 gene

  • Compare commercial SPE-39 antibody staining with anti-tag antibody patterns

  • This provides gold-standard validation of antibody specificity

• Domain-specific functional studies:

  • Generate precise deletions or mutations in specific domains of SPE-39

  • Use antibodies to assess how these mutations affect localization and interactions

  • This approach can map functional domains more precisely than RNAi knockdown

• Cell type-specific analysis:

  • Create cell type-specific SPE-39 knockout models

  • Use antibodies to confirm deletion and study compensatory changes

  • This allows examination of tissue-specific functions beyond what was observed in C. elegans spermatocytes, oocytes, and coelomocytes

• Humanized model systems:

  • Replace endogenous SPE-39 with human C14orf133 in model organisms

  • Use species-specific antibodies to confirm expression and study function

  • This approach can reveal conserved versus species-specific aspects of SPE-39 function

• Regulatory element analysis:

  • Edit promoter or enhancer regions of SPE-39

  • Use antibodies to quantify resulting expression changes

  • This helps understand the transcriptional regulation of SPE-39

What are the best strategies for developing antibodies against post-translationally modified forms of SPE-39?

Developing modification-specific antibodies requires specialized approaches:

• Modification site identification:

  • Use mass spectrometry to identify specific phosphorylation, ubiquitination, or other modification sites on SPE-39

  • Focus on modifications that change in response to cellular conditions or are at conserved residues

  • Prioritize modifications near known functional domains or interaction sites

• Modified peptide immunization:

  • Synthesize peptides containing the exact modification of interest

  • Use carrier proteins that preserve the modification during immunization

  • Employ immunization protocols optimized for modified epitopes

• Rigorous validation:

  • Test antibody reactivity against unmodified SPE-39 to ensure specificity

  • Validate using cell treatments that alter modification status (phosphatase inhibitors, deubiquitinating enzyme inhibitors)

  • Confirm specificity using SPE-39 mutants where the modification site is altered

• Application optimization:

  • Develop specialized protocols that preserve labile modifications

  • Include appropriate inhibitors in all buffers to maintain modification status

  • Consider fixation methods that specifically preserve the modification of interest

• Functional correlation:

  • Use modification-specific antibodies to track changes under conditions that affect SPE-39 function

  • Correlate modification status with interaction patterns or localization

  • Investigate how modifications might regulate SPE-39's role in vesicular trafficking and lysosomal delivery

How can super-resolution microscopy improve our understanding of SPE-39 distribution and function?

Super-resolution microscopy techniques offer unprecedented insights into SPE-39 biology:

• Nanoscale localization:

  • Techniques like STORM, PALM, or STED can resolve SPE-39 distribution below the diffraction limit

  • This allows visualization of SPE-39 organization within endosomal subdomains

  • Can reveal whether SPE-39 forms clusters or is uniformly distributed on endosomal membranes

• Multi-color super-resolution:

  • Precisely map SPE-39 localization relative to interaction partners like VPS33A and VPS33B

  • Determine whether SPE-39 and HOPS complex components form distinct or overlapping domains

  • Examine the spatial relationship between SPE-39 and RAB proteins on endosomal membranes

• Structural organization insights:

  • Study the architectural details of the vesicular structures that accumulate in spe-39 mutants

  • Examine how SPE-39 organizes at membrane contact sites during vesicle fusion events

  • Investigate whether SPE-39 forms specific structural patterns during multivesicular body formation

• Temporal dynamics:

  • Super-resolution live-cell imaging can track SPE-39 movement with nanometer precision

  • This allows correlation between SPE-39 redistribution and vesicle fusion events

  • Can reveal how SPE-39 organization changes during processes like endosome maturation

• Quantitative spatial analysis:

  • Precise measurement of SPE-39 distances from other endosomal proteins

  • Statistical analysis of clustering patterns in normal versus disease states

  • Correlation of spatial organization with functional outcomes in vesicular trafficking